BR0213078A - Anticorpo recombinante anti-osteopontina e uso do mesmo - Google Patents

Anticorpo recombinante anti-osteopontina e uso do mesmo

Info

Publication number
BR0213078A
BR0213078A BR0213078-5A BR0213078A BR0213078A BR 0213078 A BR0213078 A BR 0213078A BR 0213078 A BR0213078 A BR 0213078A BR 0213078 A BR0213078 A BR 0213078A
Authority
BR
Brazil
Prior art keywords
osteopontin
antibody
rheumatism
rheumatoid arthritis
recombinant anti
Prior art date
Application number
BR0213078-5A
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Nobuchika Yamamoto
Hirofumi Higuchi
Masaharu Torikai
Yoshiyuki Tokieda
Toshihiro Nakashima
Hiroaki Maeda
Original Assignee
Fujisawa Pharmaceutical Co
Immuno Biological Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co, Immuno Biological Lab Co Ltd filed Critical Fujisawa Pharmaceutical Co
Publication of BR0213078A publication Critical patent/BR0213078A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTICORPO RECOMBINANTE ANTI-OSTEOPONTINA E USO DO MESMO". No qual pelo menos uma região constante na cadeia pesada e na cadeia leve foram convertidas dentro de regiões humanas originais e o qual inibe a ligação de uma integrina que reconhece a seq³ência RGD para a osteopontina ou seus fragmentos e inibe a ligação de uma integrina que reconhece a seq³ência SVVYGLR ou uma seq³ência correspondente da mesma para a osteopontina ou seus fragmentos. Este anticorpo é útil como um remédio para doenças autoimunes e um remédio para reumatismo ou artrite reumatóide. Assim, é provido um método para tratar doenças autoimunes, reumatismo ou artrite reumatóide. Este anticorpo anti-osteopontina é útil em diagnósticos de reumatismos, e também em um método para diagnosticar artrite reumatóide.
BR0213078-5A 2001-09-25 2002-09-25 Anticorpo recombinante anti-osteopontina e uso do mesmo BR0213078A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001290700 2001-09-25
PCT/JP2002/009868 WO2003027151A1 (fr) 2001-09-25 2002-09-25 Anticorps recombinant anti-osteopontine et son utilisation

Publications (1)

Publication Number Publication Date
BR0213078A true BR0213078A (pt) 2004-11-23

Family

ID=19112969

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213078-5A BR0213078A (pt) 2001-09-25 2002-09-25 Anticorpo recombinante anti-osteopontina e uso do mesmo

Country Status (16)

Country Link
US (1) US7241873B2 (pt)
EP (1) EP1431310A4 (pt)
JP (1) JPWO2003027151A1 (pt)
KR (1) KR20040048899A (pt)
CN (1) CN100352844C (pt)
AU (1) AU2002332290B2 (pt)
BR (1) BR0213078A (pt)
CA (1) CA2461529A1 (pt)
HK (1) HK1084127A1 (pt)
HU (1) HUP0402049A3 (pt)
MX (1) MXPA04002837A (pt)
NO (1) NO20041225L (pt)
NZ (1) NZ531818A (pt)
PL (1) PL369446A1 (pt)
RU (1) RU2305111C2 (pt)
WO (1) WO2003027151A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
CA2461529A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
US7794948B2 (en) * 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
DE602005009925D1 (de) * 2004-02-27 2008-11-06 Roche Diagnostics Gmbh Verfahren zur beurteilung rheumatoider arthritis durch messen von anti-ccp und serumamyloid a
CA2552425C (en) * 2004-02-27 2018-02-06 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
WO2006116793A1 (en) * 2005-05-04 2006-11-09 Australian Stem Cell Centre Limited Selecting, culturing and creating lineage committed hematopoietic stem cells
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
JP4064441B2 (ja) 2006-05-31 2008-03-19 アステラス製薬株式会社 ヒト化抗ヒトオステオポンチン抗体
CN101528777B (zh) * 2006-10-26 2013-03-27 株式会社遗传科技 抗胞外基质蛋白的rgd氨基酸序列的抗体及其制法与用途
EP2132568B1 (en) * 2007-03-30 2013-05-29 Chu Sainte-justine Method of determining risk of scoliosis
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
EP2487190A3 (en) 2007-07-13 2012-11-14 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
BRPI0820885B8 (pt) * 2007-12-13 2021-03-02 Monsanto Technolgoy Llc "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
PT2243829E (pt) * 2008-01-11 2014-10-24 Astellas Pharma Inc Anticorpo anti-integrina-alfa9 humana humanizado melhorado
WO2009131256A1 (en) * 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
CA2722466A1 (en) * 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) * 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009149189A2 (en) * 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP5674654B2 (ja) * 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
AU2009340658B2 (en) 2009-02-23 2015-02-26 Gene Techno Science Co., Ltd. Anti-human alpha9 integrin antibody and use thereof
JP2012525441A (ja) * 2009-05-01 2012-10-22 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびこの使用
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
CN102712921B (zh) * 2009-09-24 2017-03-01 株式会社遗传科技 特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途
EP2488658A4 (en) * 2009-10-15 2013-06-19 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR083705A1 (es) * 2010-11-04 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9045539B2 (en) 2011-05-27 2015-06-02 Kalobios Pharmaceuticals, Inc. Anti-EMR1 antibodies
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
AU2015300080B2 (en) * 2014-08-06 2021-04-01 Mach5 Therapeutics, Inc. New anti-human Igbeta antibody
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10349259B2 (en) * 2016-09-23 2019-07-09 Apple Inc. Broadcasting a device state in a wireless communication network
AU2020331301A1 (en) * 2019-08-09 2022-02-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic antibodies against osteopontin
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US125023A (en) * 1872-03-26 Improvement in sand dredging-machines
US239400A (en) * 1881-03-29 Tobacco-fork
US1408113A (en) * 1921-01-28 1922-02-28 Mason Richard Colbert Well-measuring device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0690132T3 (da) 1993-03-11 2004-04-13 Chemo Sero Therapeut Res Inst Monoklonalt anti-HIV-antistof
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
CA2263942A1 (en) 1996-08-22 1998-02-26 Children's Medical Center Corporation Novel osteopontin derived chemotactic peptides and methods of use
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
US6509026B1 (en) 1997-08-15 2003-01-21 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
CA2251263A1 (en) * 1997-11-14 1999-05-14 Hajime Karasuyama Transgenic animal allergy models and methods for their use
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
JP2003517284A (ja) 1999-04-15 2003-05-27 チルドレンズ メディカル センター コーポレーション 免疫応答を変調する方法及び組成物
MXPA01010403A (es) 1999-04-15 2004-09-10 Childrens Medical Center Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
WO2001071358A1 (en) 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
EP1326656A2 (en) 2000-10-18 2003-07-16 Children's Medical Center Corporation Osteopontin-coated surfaces and methods of use
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
KR100932465B1 (ko) 2001-07-19 2009-12-17 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 ＩｇＥ 수용체 항체 및 항체 단편
CA2461529A1 (en) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
AU2002357748A1 (en) 2001-11-21 2003-06-10 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CN103518888A (zh) * 2013-10-14 2014-01-22 李民庆 一种养心宁神茶配方

Also Published As

Publication number Publication date
US20060002923A1 (en) 2006-01-05
EP1431310A4 (en) 2005-03-23
US7241873B2 (en) 2007-07-10
JPWO2003027151A1 (ja) 2005-01-06
PL369446A1 (en) 2005-04-18
MXPA04002837A (es) 2005-11-04
CN1688604A (zh) 2005-10-26
RU2305111C2 (ru) 2007-08-27
RU2004112540A (ru) 2005-04-20
HUP0402049A3 (en) 2009-04-28
WO2003027151A1 (fr) 2003-04-03
HK1084127A1 (en) 2006-07-21
KR20040048899A (ko) 2004-06-10
CA2461529A1 (en) 2003-04-03
NZ531818A (en) 2005-10-28
NO20041225L (no) 2004-05-25
AU2002332290B2 (en) 2007-11-08
EP1431310A1 (en) 2004-06-23
CN100352844C (zh) 2007-12-05
HUP0402049A2 (hu) 2005-01-28

Similar Documents

Publication Publication Date Title
BR0213078A (pt) Anticorpo recombinante anti-osteopontina e uso do mesmo
DK0616613T3 (da) Fragmenter af prionprotein
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
BR0208809A (pt) Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo
ES2196098T3 (es) Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
GR3035926T3 (en) Bispecific trigger molecules recognizing lymphocyte antigen CD2 and tumor antigens.
BR9814904A (pt) Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.
FI960567A (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
DE59010826D1 (de) Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung
BR9812125A (pt) Dispositivos óticos formados a partir de materiais termoplásticos fundidos processáveis, tendo um alto ìndice de refração
ES2126145T3 (es) Redireccionamiento de anticuerpos.
AR036189A1 (es) Anticuerpos de interleuquina-1beta
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ES2072423T3 (es) Anticuerpo monoclonal e inmunoensayo para el factor beta xiia de coagulacion de la sangre.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
Gupta et al. A fixed point theorem for the weak Kleene valuation scheme
DE3885975T2 (de) Monoklonale Antikörper gegen menschliche alpha-Atrialnatriüretic-Polypeptide und entsprechende Hybridome, deren Herstellung und Verwendung.
DE59208463D1 (de) Leuchtenabdeckung, insbesondere für leuchtstofflampen
ES2125977T3 (es) Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.
Byrnes 'A pauper's shame': A biocultural investigation of trauma, impairment, and disability in the Erie County Poorhouse Cemetery, 1851-1913
ES2082040T3 (es) Anticuerpos monoclonales que reconocen a la fosfolipasa a2 de membrana e inmunoensayos de fosfolipasa a2 de membrana.
AR014811A1 (es) Un peptido que enlaza anticuerpos con elevados niveles de pacientes esquizofrenicos, un ensayo para el diagnostico de la esquizofrenia y un equipopara el uso en el diagnostico de esquizofrenia
GR862472B (en) Determination of antibodies specific of hsv-1 herpes or hsv-2 in human serum with the elisa technic using the specific antigen of hsv-1 or hsv-2 type in semi - clean form
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. (JP) , YA

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. (JP) , AS

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B25A Requested transfer of rights approved

Owner name: ASTELLAS PHARMA INC. (JP) , JURIDICAL FOUNDATION T

Free format text: TRANSFERIDO DE: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.